Literature DB >> 10507627

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome.

A Khongphatthanayothin1, P C Wong, Y Samara, C J Newth, W J Wells, V A Starnes, A C Chang.   

Abstract

OBJECTIVES: a) To describe the postoperative course and outcome of cardiac surgery in children with recent respiratory syncytial virus (RSV) infection; and b) to evaluate whether timing of surgery has any impact on the outcome.
DESIGN: Retrospective case series.
SETTING: Intensive care unit and medical and surgical wards of a teaching pediatric hospital. PATIENTS: Twenty-five children (aged 25 days to 3.5 yrs; median, 4 months) with congenital heart disease who had cardiac surgery within 6 months after RSV infection.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We reviewed the clinical course and outcome of all patients. The cardiac diagnoses included ventricular septal defect (n = 11), tetralogy of Fallot (n = 3), atrioventricular canal (n = 3), and others (n = 8). Thirteen patients had surgery during the same admission as RSV infection (group I), and 12 patients had surgery electively after being discharged to home after RSV infection (group II). Two patients in group I died; both of these patients had undergone total repair of tetralogy of Fallot within 2 wks after admission for RSV infection. Postoperative complications in group I patients included pulmonary hypertension (n = 5), adult respiratory distress syndrome (n = 1), tracheal stenosis (n = 1), left ventricular dysfunction (n = 1), pericardial effusion (n = 1), secondary bacterial or fungal infection (n = 7), and deep venous thrombosis (n = 1). Of all group I patients, the ones who were operated on early appeared to be at higher risk for complications, especially for postoperative pulmonary hypertension. No patient in group II died, and only two patients had minor complications (one had reactive airway disease, and the other had a transient superior vena cava syndrome after a bidirectional Glenn operation).
CONCLUSIONS: Cardiac surgery performed during the symptomatic period of RSV infection is associated with a high risk of postoperative complications, especially postoperative pulmonary hypertension. These complications appeared to be more frequent and of greater severity in patients who had earlier surgery compared with those who had later surgery. More studies are needed regarding the proper timing of cardiac surgery in patients with congenital heart disease and RSV infection.

Entities:  

Mesh:

Year:  1999        PMID: 10507627     DOI: 10.1097/00003246-199909000-00042

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

Review 1.  Mechanical cardiopulmonary support in children and young adults: extracorporeal membrane oxygenation, ventricular assist devices, and long-term support devices.

Authors:  A C Chang; E D McKenzie
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

3.  Use of palivizumab in children with congenital heart disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

4.  New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis.

Authors:  Dai Kimura; Jordy Saravia; Sridhar Jaligama; Isabella McNamara; Luan D Vu; Ryan D Sullivan; Salvatore Mancarella; Dahui You; Stephania A Cormier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

5.  The impact of human rhinovirus infection in pediatric patients undergoing heart surgery.

Authors:  Claudia Delgado-Corcoran; Madolin K Witte; Krow Ampofo; Ramon Castillo; Stephanie Bodily; Susan L Bratton
Journal:  Pediatr Cardiol       Date:  2014-06-18       Impact factor: 1.655

6.  Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

Authors:  Andrew Warren; Joanne M Langley; Wanda Thomas; Jeff Scott
Journal:  Can J Cardiol       Date:  2007-05-01       Impact factor: 5.223

7.  Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.

Authors:  Stuart A Cohen; Robert Zanni; Alan Cohen; Molly Harrington; Paul VanVeldhuisen; Marnie L Boron
Journal:  Pediatr Cardiol       Date:  2007-10-10       Impact factor: 1.655

8.  Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

Authors:  Marc Bellavance; Charles V Rohlicek; Jean-Luc Bigras; Jean-Marc Côté; Marc Paquet; Marc H Lebel; Andrew S Mackie
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

9.  Impact of Viral PCR Positive Nasal Swabs (Non Covid-19) on Outcomes Following Cardiac Surgery.

Authors:  Virginia Kathleen Cox; Diane Hersey; Melissa Valentine; Keyana Richardson; Lanette Johnson; Mark Galantowicz; Janet M Simsic
Journal:  Pediatr Cardiol       Date:  2021-05-13       Impact factor: 1.655

10.  Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey.

Authors:  Jo Won Jung
Journal:  Korean J Pediatr       Date:  2011-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.